Diamyd Medical's Precision Medicine patent for the prevention and treatment of autoimmune diabetes granted in South Korea

The patent, granted by the South Korean Patent Office and valid until 2035, safeguards the application of GAD autoantigen in treating or preventing autoimmune diabetes, specifically in individuals with the HLA DR3-DQ2 gene. GAD, the key component in Diamyd[®], an antigen-specific immunotherapy, currently under evaluation in the registrational Phase III trial DIAGNODE-3. This trial is recruiting patients with recent-onset Type 1 Diabetes across eight European countries and the US.HLA DR3-DQ2 is a genetic marker linked to Type 1 Diabetes, found in up to 40% of those with the disease. The